Performance beat was driven by robust market share gains in immunology and neuroscience, which management describes as the company's primary growth engines. Skyrizi's outperformance is attributed to its best-in-class profile and leadership in psoriatic disease, where it maintains a share lead of over 4x versus the nearest competitor. The neuroscience portfolio is achieving industry leadership status, with migraine and psychiatry franchises delivering double-digit growth and share gains. Management is utiliz ...